Daniel R Owens

发表

The Effect of Haematocrit on Measurement of the Mid-Infrared Refractive Index of Plasma in Whole Blood

G. Mashanovich, S. Faust, D. Rowe, 2021, Biosensors.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Nguyen H. Tran, Kathryn Jones, Tao Dong, 2020, The Lancet.

Incidental findings in UK healthy volunteers screened for a COVID‐19 vaccine trial

S. Faust, A. Pollard, S. Mehdipour, 2021, Clinical and translational science.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Problem-solving in clinical practice: Persisting respiratory distress in a premature infant

S. Faust, M. Iro, C. Jones, 2020, Archives of Disease in Childhood.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

A. Pollard, P. Aley, L. Godfrey, 2022, The Lancet.

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

J. Haughney, V. Libri, G. Screaton, 2022, Journal of Infection.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Nguyen H. Tran, Andreas C. Themistocleous, David J. Smith, 2020, Lancet.

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Scott M Elliott, J. Haughney, V. Libri, 2021, The Lancet.

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

J. Haughney, V. Libri, M. Kamal, 2022, The Lancet Infectious Diseases.

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Jonathon P. Baker, F. Hayden, W. Greenhalf, 2022, The Lancet Infectious Diseases.

High frequency of paediatric facial nerve palsy due to Lyme disease in a geographically endemic region.

S. Faust, R. Dorey, C. Jones, 2020, International journal of pediatric otorhinolaryngology.

COVID-19 symptom surveillance in immunocompromised children and young people in the UK: a prospective observational cohort study

S. Faust, Daniel R Owens, H. de Graaf, 2021, BMJ Open.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

A. Borobia, H. Schuitemaker, Andrew Gibson, 2022, The Lancet Infectious Diseases.

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

J. Haughney, V. Libri, J. Nguyen-Van-Tam, 2023, Journal of Infection.

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

S. McCormack, V. Libri, A. Winston, 2023, eClinicalMedicine.